JAGIELSKA, Beata et al.
Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS).
Molecular and Cellular Therapies, [S.l.], v. 6, n. 1, jan. 2018.
Available at: <http://molcelltherapies.com/article/view/202>. Date accessed: 23 june 2018.